Back to List View Graph View

Tocilizumab

Tocilizumab is a therapeutic monoclonal antibody that inhibits interleukin-6 receptor (IL-6R) Signaling.

Where the papers sit

11 papers from the last 6 months study tocilizumab directly · updated from PubMed 12 Nov 2026

Study type 0 clinical trials · 10 observational · 1 human data

Themes 3 themes

  • Rheumatoid Arthritis Safety and Response

    Rheumatoid arthritis care is moving toward individualized tocilizumab selection and safety monitoring. Interpretable clinical-data models aim to predict response, while observational work focuses on infection risk, including hydroxychloroquine exposure. Cutaneous leishmaniasis and pediatric pharmacovigilance findings emphasize opportunistic infection and broader safety surveillance. The recurring priority is risk stratification rather than efficacy alone.

    4 papers · 36.4%

  • Giant Cell Arteritis Treatment

    Glucocorticoid-sparing treatment is the central question in giant cell arteritis, with tocilizumab compared with methotrexate and steroid monotherapy. Real-world care remains glucocorticoid-heavy, while combination strategies are assessed for efficacy through 78 weeks. Tocilizumab is associated with fewer major adverse cardiovascular events, but serious infections remain a key safety endpoint. The evidence is moving toward longer-term steroid reduction and comparative safety assessment.

    3 papers · 27.3%

  • Others — Cross-Disease Clinical Evidence

    Evidence spans Takayasu arteritis, drug-induced liver injury, severe COVID-19 and thyroid eye disease rather than one unified indication. Tocilizumab is reported alongside adjunctive HydroBox, compared with anakinra, and tested at fixed versus weight-based doses. Outcomes range from ischemia and mortality to atypical hepatic injury and thyroid eye disease response. These reports provide disease-specific signals, but their heterogeneity does not support a single clinical direction.

    4 papers · 36.4%

Papers

The 11 papers from the last 6 months that study tocilizumab directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Rheumatoid Arthritis Safety and Response (4)
  1. Safety signals of tocilizumab in pediatric patients: A real-world pharmacovigilance analysis based on the FAERS database with network pharmacology insights. Human vaccines & immunotherapeutics · 14 Oct 2026 PMID 42873988
  2. Interpretable machine learning models for predicting tocilizumab response in rheumatoid arthritis using clinical data. BMC medical informatics and decision making · 29 Sept 2026 PMID 42806362
  3. Reactivation of Cutaneous Leishmaniasis in a Rheumatoid Arthritis Patient Undergoing Tocilizumab Treatment. The American journal of tropical medicine and hygiene · 15 Sept 2026 PMID 42743917
  4. Risk factors for infection in rheumatoid arthritis patients treated with tocilizumab: an observational study highlighting hydroxychloroquine use. Clinical rheumatology · 18 Aug 2026 PMID 42611374
Giant Cell Arteritis Treatment (3)
  1. Tocilizumab Is Associated With a Lower Incidence of Major Adverse Cardiovascular Events in Giant Cell Arteritis. Circulation · 29 Aug 2026 PMID 42667206
  2. Glucocorticoid in giant cell arteritis: real-world treatment patterns over time and associated burden in a nationwide hospital-based study within the French health insurance database. RMD open · 7 Jul 2026 PMID 42414038
  3. Glucocorticoid monotherapy versus combination with methotrexate or tocilizumab in giant cell arteritis: efficacy and safety at 78 weeks in a retrospective cohort study. Medicina clinica · 28 Jun 2026 PMID 42365805
Others — Cross-Disease Clinical Evidence (4)
  1. Sustained Tocilizumab and Adjunctive HydroBox Therapy in Refractory Takayasu Arteritis: An 11-year Case Report. In vivo (Athens, Greece) · 29 Oct 2026 PMID 42957267
  2. Effects of fixed dose versus weight-based tocilizumab on thyroid eye disease: a single-centre retrospective observational pilot study. International ophthalmology · 29 Oct 2026 PMID 42955449
  3. Drug-Induced Liver Injury During Treatment With Tocilizumab: A Case Report of an Atypical Pattern Lesion. Pharmacology research & perspectives · 22 Sept 2026 PMID 42768705
  4. Comparative associations of Anakinra and Tocilizumab initiation with in-hospital mortality in severe COVID-19: A single-center sequential cohort study. PloS one · 2 Sept 2026 PMID 42685097

By study type

Observational studies and case reports (10)
  1. Sustained Tocilizumab and Adjunctive HydroBox Therapy in Refractory Takayasu Arteritis: An 11-year Case Report. In vivo (Athens, Greece) · 29 Oct 2026 PMID 42957267
  2. Effects of fixed dose versus weight-based tocilizumab on thyroid eye disease: a single-centre retrospective observational pilot study. International ophthalmology · 29 Oct 2026 PMID 42955449
  3. Safety signals of tocilizumab in pediatric patients: A real-world pharmacovigilance analysis based on the FAERS database with network pharmacology insights. Human vaccines & immunotherapeutics · 14 Oct 2026 PMID 42873988
  4. Drug-Induced Liver Injury During Treatment With Tocilizumab: A Case Report of an Atypical Pattern Lesion. Pharmacology research & perspectives · 22 Sept 2026 PMID 42768705
  5. Reactivation of Cutaneous Leishmaniasis in a Rheumatoid Arthritis Patient Undergoing Tocilizumab Treatment. The American journal of tropical medicine and hygiene · 15 Sept 2026 PMID 42743917
  6. Comparative associations of Anakinra and Tocilizumab initiation with in-hospital mortality in severe COVID-19: A single-center sequential cohort study. PloS one · 2 Sept 2026 PMID 42685097
  7. Tocilizumab Is Associated With a Lower Incidence of Major Adverse Cardiovascular Events in Giant Cell Arteritis. Circulation · 29 Aug 2026 PMID 42667206
  8. Risk factors for infection in rheumatoid arthritis patients treated with tocilizumab: an observational study highlighting hydroxychloroquine use. Clinical rheumatology · 18 Aug 2026 PMID 42611374
  9. Glucocorticoid in giant cell arteritis: real-world treatment patterns over time and associated burden in a nationwide hospital-based study within the French health insurance database. RMD open · 7 Jul 2026 PMID 42414038
  10. Glucocorticoid monotherapy versus combination with methotrexate or tocilizumab in giant cell arteritis: efficacy and safety at 78 weeks in a retrospective cohort study. Medicina clinica · 28 Jun 2026 PMID 42365805
Human data, design not indexed (1)
  1. Interpretable machine learning models for predicting tocilizumab response in rheumatoid arthritis using clinical data. BMC medical informatics and decision making · 29 Sept 2026 PMID 42806362